Evidence map›Paper›PMID 29660936›Full record

Trial reportJournal of Alzheimer's disease : JAD2018

Associations of Angiotensin Converting Enzyme-1 and Angiotensin II Blood Levels and Cognitive Function.

Sevil Yasar, Vijay R Varma, Gregory C Harris, Michelle C Carlson

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of Alzheimer's disease : JAD, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. International journal of molecular sciences · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Higher Angiotensin II Type 1 Receptor Levels and Activity in the Postmortem Brains of Older Persons with Alzheimer's Dementia.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Sevil YasarDepartment of Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
Vijay R VarmaNational Institute on Aging, Intramural Research Program, Laboratory of Behavioral Neuroscience, Baltimore, MD, USA.
Gregory C HarrisWay Station Inc., Columbia, MD, USA.
Michelle C CarlsonDepartment of Mental Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA.
Johns Hopkins University · USAmway (United States) · USNational Institute on Aging · US

Funding

'T V ASSESSMENT - MEMORY DISORDERED PATIENTS'P50AG005146 · JOHNS HOPKINS UNIVERSITY · 1985 to 2005
$10.4M
Technological Assessment and Solutions Core - RC4P30AG021334 · JOHNS HOPKINS UNIVERSITY · 2003 to 2025
$6.1M
Pathogenesis of physical disability in Aging womenR37AG019905 · JOHNS HOPKINS UNIVERSITY · 2001 to 2005
$4.6M
Intramural NIH HHS Z99 AG999999NCATS NIH HHS UL1 TR001079NIA NIH HHS P01 AG027735NIA NIH HHS P30 AG021334NIA NIH HHS P50 AG005146NIA NIH HHS R37 AG019905
6 · The paper itself

Abstract

backgroundEmerging evidence suggests a possible role of the renin angiotensin system in the pathophysiologic process of Alzheimer's disease, of which angiotensin converting enzyme-1 (ACE-1) and angiotensin II (ANGII) are important proteins. Few studies evaluated associations between blood ACE-1 and none between ANGII levels, and cognition.

objectiveOur pilot study was aimed to examine associations between blood ACE-1 and ANG II levels and cognitive function in non-demented participants at baseline and over a 1-year period.

methods56 participants were included from the Brain Health Substudy of the Baltimore Experience Corps Study. Linear regression analysis, adjusting for confounders, was used to determine associations between baseline ACE-1 and ANGII, and baseline and 1-year follow-up measures of psychomotor and processing speed, executive function, verbal learning memory and working memory, and whether these associations were mediated by blood pressure.

resultsParticipants were predominantly female (75%), African-American (93%), with mean age of 67.8 years and education of 14.3 years. There were no associations between baseline ACE-1 or ANGII levels and cognitive function; however, there were significant association between baseline ACE-1 levels and 1-year follow-up Trail Making Test, Part A (β= 0.003, p = 0.04) and Digit Span (β= -0.001, p = 0.02).

conclusionsIn this cognitively intact sample, elevated ACE-1 levels were associated with worse processing speed and working memory after 1 year. Findings from this pilot study suggest that changes in the RAS are associated with alterations in cognitive function warranting further assessment of the role of RAS in neurodegenerative disorders.

Indexed as

CognitionAgedAngiotensin IIBiomarkersFemaleFollow-Up StudiesHumansMalePeptidyl-Dipeptidase APilot ProjectsACE protein, humanAngiotensin IIBiomarkersPeptidyl-Dipeptidase Aangiotensin converting enzyme-1Angiotensin IIcognitioncohort study

Identifiers

PMID29660936
PMCPMC5998658
OpenAlexW2796924500

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.